Goldman Sachs
ROIV icon

Goldman Sachs’s Roivant Sciences ROIV Stock Holding History

Goldman Sachs’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$657M Buy
18,556,458
+7,444,867
+67% +$220M 0.06% 322
2026
Q1 		$308M Buy
11,111,591
+128,908
+1% +$3.31M 0.04% 493
2025
Q4 		$238M Buy
10,982,683
+8,621,617
+365% +$170M 0.03% 568
2025
Q3 		$35.7M Sell
2,361,066
-576,301
-20% -$7.13M ﹤0.01% 1700
2025
Q2 		$33.1M Buy
2,937,367
+503,981
+21% +$5.46M ﹤0.01% 1669
2025
Q1 		$24.6M Buy
2,433,386
+324,764
+15% +$3.51M ﹤0.01% 1833
2024
Q4 		$24.9M Sell
2,108,622
-3,283,753
-61% -$38.8M ﹤0.01% 1900
2024
Q3 		$62.2M Buy
5,392,375
+1,191,040
+28% +$13.6M 0.01% 1081
2024
Q2 		$44.4M Buy
4,201,335
+2,702,419
+180% +$29.6M 0.01% 1247
2024
Q1 		$15.8M Buy
1,498,916
+1,085,821
+263% +$11.7M ﹤0.01% 2037
2023
Q4 		$4.64M Buy
413,095
+170,966
+71% +$1.67M ﹤0.01% 3224
2023
Q3 		$2.83M Buy
242,129
+142,981
+144% +$1.62M ﹤0.01% 3485
2023
Q2 		$999K Sell
99,148
-1,676,043
-94% -$15M ﹤0.01% 4336
2023
Q1 		$13.1M Buy
1,775,191
+1,253,849
+241% +$10.3M ﹤0.01% 2175
2022
Q4 		$4.17M Buy
521,342
+322,742
+163% +$1.8M ﹤0.01% 3328
2022
Q3 		$639K Sell
198,600
-2,680
-1% -$10.4K ﹤0.01% 4809
2022
Q2 		$819K Buy
201,280
+181,089
+897% +$719K ﹤0.01% 4769
2022
Q1 		$100K Buy
+20,191
New +$133K ﹤0.01% 6108

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's ROIV Position: Q2 2026 in Review

Goldman Sachs increased its Roivant Sciences (ROIV) stake by 67% in Q2 2026, buying an estimated $220M and bringing the position to 18,556,458 shares worth $657M. The position accounts for 0.06% of the portfolio, ranked #322.

Goldman Sachs first reported a position in ROIV in Q1 2022 and has held it in 18 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Goldman Sachs held 18,556,458 shares of Roivant Sciences worth $657M as of Q2 2026.
  • Goldman Sachs bought 7,444,867 Roivant Sciences shares in Q2 2026, an estimated $220M.
  • Roivant Sciences made up 0.06% of Goldman Sachs's portfolio in Q2 2026, its #322 holding.
  • Goldman Sachs first reported a position in Roivant Sciences in Q1 2022 and has held it in 18 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.